Replay available

Bajaj Healthcare (NSE:BAJAJHCARE) Q2 2027 Earnings Call

Bajaj Healthcare (NSE:BAJAJHCARE) Q2 2027 earnings call, held 2026-10-19. Watch the replay and read the transcript on 6ix.

Mon, October 19, 2026 at 9:44 AMendedReplay
Bajaj Healthcare (NSE:BAJAJHCARE) Q2 2027 Earnings Call
Company
Bajaj Healthcare Ltd (NSE:BAJAJHCARE)
Period
Q2 2027 earnings call
Date
Mon, Oct 19, 2026, 9:44 AM ET
Replay
Watch the replay on this page · 46 min

On 6ix: 6ix.com/event/bajaj-healthcare-limited-bajajhcare-q2-2027-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Ladies and gentlemen, good day, and welcome to Bajaj Healthcare Limited Q2 and H1 FY 'twenty seven Earnings Conference Call. As a reminder, all participants' line will be in the listen only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Please note that this conference is being recorded. I now hand over the conference to Ms. Tachi Ambrev from MUFG Investor Relations. Thank you, and over to you, ma'am. Thank you,. Good evening, everyone. On behalf of Bajaj Healthcare Limited, I extend a warm welcome to all the participants on the Q2 and H1 FY 'twenty seven earnings conference call. Today, on the call, we have Mr. Anil Jain, Managing Director and Mr. Rohan Parekh, Chief Financial Officer, to provide insights on the company's operational and financial performance.

0:59 Before we begin the call, I would like to give a short disclaimer. This call may contain some of the forward looking statements, which are completely based on our expectations, beliefs and opinions as of today. These statements are not a guarantee of our future performance and involve unforeseen risks and uncertainties. With this, I would like to hand over the call to Anil sir for his opening remarks. Over to you, sir. Thank you. Very good evening to everyone. On behalf of Bajaj Healthcare team, it is my privilege to welcome you to our earnings call for the second quarter and the first half of twenty twenty seven. With us, we have today our Chief Financial Officer, Mr. Rohan Parekh. Coming to the quarter, Q2 twenty twenty seven was a strong quarter.

1:48 Revenue from operations grew 18.9% Y o Y to INR 175.9 crore and profit after tax grew by 26.9%. For the first half, revenue grew about 15% and PEC about 21% in the line with the guidance we shared with you last quarter. Beyond the numbers, the quarter shows good business momentum and progress across our strategic priorities. Our combination business rebounded strongly, growing 82 year on year as we have expected at the end of Q1. API export grew 28.5% year on year.

2:35 Together, API export and formulation grossed INR 100 crores in quarterly revenue and now makes up to close to 60% of our revenue. Domestic API revenue moderated during this quarter, but grew 10.1% year on year for the first half. Recently, we have received an approval from Honorable NCLT for the acquisition of GenRx Pharmaceutical Private Limited. It strengthened our combination capabilities and broadened our portfolio as we build our combination franchises. The quarter also marked an important milestone in our specialty products journey. Bajaj Healthcare became the first company in India to receive DCGI approval to manufacture and market SINUVAMAT API tablet in three in six different stands.

3:30 We launched the tablet commercially in September through our eight marketing partners. SINUVAMAT is a next generation anti seizure medicine for the adult with partially onset seizure. It is a clear example for the differentiated specialty portfolio we are building. We also continue to widen our regulatory reach in the key international markets. In Brazil, we are progressing with Envisa GMP certification process and have identified 17 products for CBPF submission. In Europe, we have filed 12 CP, have been already filed till date, of which eight has been approved and four are under review.

4:18 In South Korea, we secured KDMAF approval for two more products during this quarter, taking the total duration with the KDF two seventeen. In Egypt, three products are registered under the whitelist process with 10 more planned in later phase. Alongside with this, we continue to invest in our manufacturing capabilities. The company is constructing a state of art commercial peptide manufacturing plant scheduled to complete by 03/31/2027, with an installed capacity of two fifty kgs per annum. This facility will be supported with solid phase synthesis and also with fermentation technology, focusing manufacturing of pharmaceutical, nutraceutical and cosmetic peptides.

5:11 As planned, our oncology API plan will be commencing from second quarter of financial year twenty twenty eight. The company has expanded R and D facility supported by team of over 80 experienced professionals. The R and D center focus on new product development, oncology, peptide and API research. The company has increased its R and D spending to approximate 2.5 to 3%. The company is establishing a dedicated formulation plant at Nasik with the facility for oral solid oral dosage form, tablet, sachet and capsules. Nasal, oral oncology, nutraceutical and ointment.

6:01 The plan is expected to operational by first quarter of FY 'twenty eight. The company has established a business vertical focus on the formation export with the objective of registering the marketing branded generic formation across rest of the world. Docea has been submitting several markets, including Africa, Myanmar, Philippines, Vietnam and Latin America. The company has established a strong business foundation in industries presence and operational capabilities. Building up this legacy, the company is now strengthening its leadership structure by appointing a key management person who are experienced professionals with proven expertise in their respective fields.

6:48 Last year, we have appointed Mr. Srikumar Nair, who has joined as a Chief Operating Officer with more than forty years of experience in the pharma operation. Further, we have appointed Mr. AG Prasad, leading our Institute of Sales and Marketing, having thirty five years of experience. Also, have appointed Mr. EJ Babu, lead our global API business, having thirty three years of experience in API industries. Apart from this, we have appointed Mr. Bajaj, who is taking care of our R and D and he is our R and D Head Mr. Sujay Banerjee for the ROW branded generic formulation and Mr. Rahul Senap as our Oncology Sales and Business Head for our Oncology Division.

7:37 This initiative marks an important milestone in our company journey towards building a more professional management, instantly driven and further ready organization future ready organization. Looking ahead, our aim is to reach a revenue of INR 902,000 crore by FY 'twenty nine with an EBITDA margin of 18% to 21%. With that, I will hand over to Mr. Ron Parikh, who will take you through the financial performance for the quarter and the half first half in more detail. Thank you, everyone. Thank you, Anil sir, and good evening to everyone. Let me take you through our financial performance. Revenue from operations for the quarter was INR 175.9 crores, up by 18.9% Y o Y and 6.2% sequentially.

8:31 For the first half of the year, every 4% grew 15.1% Y o Y to INR 341.5 crores from INR 296.8 crores in H1 last year. Domestic API revenue was INR 71.6 crores in quarter two as compared to INR 76.3 crores in quarter two last year and INR 92 crores in quarter one of this year. For the first half, domestic API revenue grew by 10.1% Y o Y to INR 163 crore. Export API revenue was INR 62.6 crore, up by 28.5 Y o Y from 48.7% in quarter two of last year and up by 25.1% from INR 50.1 crores in quarter one this year. For the first half, API revenue grew by 11% Y o Y. The formations revenue was 41.7%, up by 82% as compared to the previous quarter and INR 22.9 crores in September twenty twenty five quarter.

9:34 It is nearly 79% growth. For the first half, formation grew by 38.4% Y o Y to INR 65 crores. Gross profit grew by 12.4% Y o Y to INR 85.4 crores with a gross margin of 48.3%, which is in line with quarter one of this year. EBITDA was 32.1, up by 12.2% from INR 28.6 crores in quarter two and up by 8.6% from INR 29.6 crores in quarter one of this year. EBITDA margin improved sequentially from INR 17.8 to INR 18.2. For the half year, gross profit grew by 14.2% to INR 165.8 with a gross margin of INR 48.3. EBITDA margin grew by 14.2% to INR 61.7 crores with EBITDA margin at about 18.1%.

10:24 Property after tax grew by 26.9% Y o Y to INR 14.1 crores and part margin improved from percent improved to 8% from 7.5% in quarter two of this year. PAT grew by 21.1% to INR 27.8 crores from INR 22.9 crores in H1 last year and a PAT margin improved from 8.1% from 7.7%. In short, the first half of the year delivered a healthy growth with profit and faster growing faster with revenue. On the balance sheet front, net worth stood at about INR $5.57 crores as of 09/30/2026, up from INR $5.83 crores in March 2026. Debt to equity remained healthy and comfortable at about 0.5x.

11:13 This reflects a stronger financial position. India Eatings and Research upgraded our rating long term ratings from A minus stable to Ind A stable in this quarter and from the short term rating to Ind A1. With that, I open the floor for further questions. Thank you. Thank you very much. We will now begin with the question and answer Participants are requested to use handset while asking a question. The first question is from the line of Bajaj Pudhadev from Ambit Asset Management. Please go ahead.

12:10 Yes. Good evening, team, and congratulations for a very good quarter. Sir, my first question is that during the quarter, you've got the approval for generics, which is a formulation facility. So is my understanding correct that now that you have got this approval, possibly the formulation which is being produced at Manjushar may be shifted to generics. And Manjushar may sort of fuel formulation exports going forward? That is my first question. My second question is that as on March 26, we've seen almost 110 DMF filings having filed, and this is 100% growth on a Y o Y basis. So when can we see revenues coming in from this DMF filings that we have done? And my last question is that we've seen some increase in terms of inventory on the working capital front. So is it more strategic in nature given the raw material inflation? And is it fair to say that maybe by year end, the working capital can also normalize? These are my three questions.

13:23 Thank you, Bajaj. Regarding the NAFIC facility, it is a strategic decision because our combination division, the sales is increasing, and we need a capacity for next next two to three years. So the new molecules, which we are developing will be manufactured at the Burra facility because that is an approved facility. And the new facility, which we got from will be doing all the other formulations, which are going to the different markets. Regarding the second question of 110 DMF. As you know, the DMF filing we have done now, we are awaiting the approvals from the regulatory bodies of the respective countries.

14:10 As and when we will be getting, it takes approximate two to three years to get an approval and to start the business. So it's in a sequence form. As you know, we have already got eight CP approvals. So that product already started the marketing, and this will take another one to two years to get the business. Third, as regards to the working capital, as you know, there is a dispute in the Gulf area. So to our facilities should not be stopped in between. So we have increased our inventory. Yes. So Bajaj, adding up for the inventory increase, this is a policy and a strategic decision by the company. We'll continue to monitor the situation for the West Asia crisis. Thank you. Great, sir. Thank you very much and all the very best.

14:59 Thank you. Thank you. The next question is from the line of Shantanu Basu from Smith Limited. Please go ahead. Hello. Can you hear me? Yes, sir. Okay. Okay. So congratulations on a good set of numbers. My question is firstly with regard to Generics. So what was the revenue potential from this entity? If you can mention that from the current year, FY '27 and FY '28 perspective, and also with regard to your oncology API plan from... Which is going to in FY '28, Q two of FY '28. So what would be the revenue potential for FY '28 and full year FY '29?

15:49 Those are my questions. Thanks. So Generics, as we are having a different divisions like Ointment, Tab A. So in next two to three years, once this facility start, we should grow around 200 crores to INR $2.50 crores from that unit. And as regards to the oncology API plant, first year will be like approval and everything will start picking up. So in next two to three years, once this plant is in operation, we should reach a revenue of around 200 crores. Okay. All right. Thank you. Thank you. The next question is from the line of Arunabh Sakuja from Ambit Capital. Please go ahead.

16:45 Hi. Thank you for taking my questions. So my first question is, can you give a bit of an indication to how the domestic API prices have moved in this quarter too? And any indication as to how you expect them to move for the remaining of the financial year? Yes. So the domestic API is more or less is all dependent upon the market condition, the demand and supply and overall the what is happening in the world. As you know, always API is always on pressure. Price pressure is there, even the demand pressure is there. So over the period of time, there's not this much improvement in the API pricing. It will be a straight line.

17:44 Got it. And what is the total expected CapEx for FY 'twenty seven? Yes. Total expected CapEx for FY '7 will be around INR 65 crores to INR 80 crores. Okay. INR 65 crores to INR 80 crores. All right. In the last call, you had given a guidance of around 10% to 15% growth in revenue and profit with an 18% to 20% margin. So are we broadly on track to achieve this? Yes, we are on track to achieve this. Okay, great. So if you see our quarter, so the growth is more than 15%, it is in the line of almost 20%.

18:32 Right. Congrats again on a strong set of numbers, and thank you for answering my questions. Thank you. The next question is from the line of from Antifragile Thinking. Please go ahead. Yes. Hi. Thank you for the opportunity. A couple of questions from my side. First is on the formulations where the revenue was up about 80% Y o Y. And we know that Sinabomate was launched in September, I think through eight partners, if I'm not mistaken. Question is, how was the secondary sales? I mean, have the secondary sales responded in line with our expectations or below or above our expectations? And should we expect this traction to continue through the second half of fiscal?

19:27 You. So we do a primary sale. We are B2B to the eight our partners. So what is that sale, still we don't have because we have launched this product in September itself. But the one good thing is that we have got a repeated orders from them. So this clearly shows that their secondary sales are moving very well. No. That's helpful, Aditi. Thank you. And on that peptide announcement, you just made, and I think it's well covered in the recent annual report as well. And by the way, the annual report reads a lot better than the previous annual report. So full credit to the team for writing the way it was written, including the cash flows and, you know, those kind of return ratios, etcetera, which normally, you know, such a small company, it's easy to skip in the annual report, but very well written.

20:26 And the question is on the peptide. See, peptides have... And many Indian companies are today talking about CDMO and peptides, almost every pharma company. Now in our case, I think the peptides have applications across nutraceuticals, cosmetics, and pharma, of course. In that context, where do you see the strongest commercial opportunity or the immediate commercial opportunity? And what specific milestones should we as investors watch for the next twelve to eighteen months to sort of know that the new facility is being built against real demand? Thank you. So as regards to peptide, as I mentioned in my first that we are not only into pharma, but we'll be concentrating more on cosmetic, which is you can see a lot of cosmetics are coming with the peptide and the nutraceuticals.

21:20 So we are into API of peptides. And if you see, there will be more than 50 to 100 companies will be launching the product. But the main key remains is the API. How many manufacturers are there in India who will be manufacturing the API? With this capacity of two fifty kgs. So we believe that we have a very good position with the peptide. And we for your information, we have already developed six APIs, which has already been developed at the pilot scale, which we have built. We have built the R and D for peptide and a pilot plant. So at the pilot level, we are absolutely ready with the six peptide. Once we start this, our commercial production, which is, as I mentioned, second quarter.

22:09 So it will take another six to ten months for the approvals with the customers. So the real turnover or turnaround of this peptide facility will be INR $28.29 crores. And where we expect the first year to be around 7,000 to INR 100 crores. And if you cumulative for next year, it will be around 300 crores. That's helpful, Anjali. And finally, on the R and D side, with the new R and D center up and running, we have integrated not many people. I mean, how are we placed in terms of r and d for not just this year, for maybe the next two years? Do we... Are we satisfied with the number of scientists that we have onboard today? How do you look at the OpEx or operational expenses on the R and D side going forward?

22:59 So as I mentioned, we already have more than 80 people working in this new R and D setup, which we started in August, where we can accumulate almost 120 more total 120 chemist can fit in. So in the first phase, we have appointed almost 80, 80 plus. And hopefully, for next three years, this R and D will be fully I mean, it will be full it will be running for next three to four years. Because in that, we have the API R and D, we have a peptide R and D, we have a separate oncology R and D and a biotechnology R and So there are four sections, and it's a complete building of r and d. Okay. So ultimately, we will have one twenty odd people. We have already got 80 of those one twenty. Yes. Okay. Okay. No. That's it.

23:51 Thank you. Thank you so much. Thank you. That's all. Thank you. Thank you. The next question is from the line of from Capital. Please go ahead. Hello. Thank you for the opportunity, My sir. Question was on your oncology API factory that's due in FY 'twenty eight. Are you expecting any your portfolio can be backward integrated? And what margins margin improvement do you expect from this backward integration of your Oncare existing portfolio? So OncoCare is a division where we do a marketing and sales of our own branded oncology product.

24:39 So what will happen, now we are dependent on the third party for these products. Once we have our own API and a formation, which is a backward and forward integrated plan, then our margin will be definitely increasing and even our sales increase because we will not only have our own branded, but we can we will be partners with other big players in India, like an example of Cinnovo, where we are partnered with eight companies. So that is the model we are looking forward. Okay. So can you just give a number or percentage on how much of your portfolio can be backward integrated and any number on margin maybe? In the next two to three years, hopefully, percent to 70% of our product will be backward integrated and revenue that will be increased of almost from current revenue.

25:37 The increase will be around 10% to 15% in margin. Yes, Thank you, sir. Thank you. The next question is from the line of Vishap Tipati from Multidimensional Thinking. Please go ahead. Hey. Hi. Thanks for taking my question. Am I audible? Yes, sir. You are audible. Okay. So, again, thanks for the annual report this time, sir. And it comes out like company is trying to structurally structurally change itself, and we talk a lot about going ahead.

26:22 It should be measured on execution. So may you help us with seeing bottlenecks, which we can see right now, which can hinder the execution and how we are planning to deal with those? Thank you. So in next year, the bottleneck will be these facilities because we are developing every year. We have put our R and D, new products will be coming. So that has been already taken care. We are right now, we are building a peptide plan. Next year, we already planned for another plan. Moreover, we are changing our product line. We are changing from a high volume to a volume low volume. So that will cover our manufacturing capacities.

27:13 Further, there was a regulatory we are moving more towards the regulatory, that was a bottleneck. So we have hired a number of good people, so they can lead this regulatory. And the third one was the bottleneck was the R and D. And that also we have taken care for next two to three years. Thank you. My next question would be, may you, sir, can confirm if our operating cash flow for this quarter was INR 15 crores approx? Yes. Sorry. This this half this half. Yeah. So so, sir, what is the year end operating cash flow program looking forward to? And, like, again, in last one call, we discussed that going ahead, we might be, like, improving the bar a bit to cash flow.

28:06 But looking at this first half, again, it looks a bit down. So any comment on that? Yes. So you can expect that the operating cash flows to be more than INR 30 crores for the financial year. With respect to the second question that you asked for the EBITDA to operating cash flow, we expect it to improve, like we mentioned in the last earnings call, but we are monitoring the situation, like I mentioned in our speech, because of the West Asia crisis, we are required to maintain certain amount of inventory with us. Just to give a feedback, we on an overall basis, the receivable turnover has improved from one hundred forty five to one hundred thirty five days. So there are improvements in each aspect of the business.

28:54 Thank you. Thank you, sir. All the best. Yes. Thank you. Thank you. The next question is from the line of Nimesh Verma from Bajaj Securities. Please go ahead. Good afternoon, sir. Am I audible? Yes. You are. Sir, my first question would be, how has the competitive intention... Intensity in the API business evolved over the last few quarters? Are there certain product categories where the pricing has started stabilizing? Prices are more or less stabilized, but we cannot predict what will happen tomorrow because it's a volatile market right away. Gulf is there. Gulf is having dispute, then the container phase, everything is increasing.

29:41 Overall, if you see the interest rate has gone up. So it is unpredictable right now. But we are monitoring the situation. And that's why if you see, we are keeping our inventory. That's why our inventory is high. Got it, sir. So the second question would be, given the current revenue mix, how has... How different are the margin profiles of domestic APIs, exports and formulations? Which segment offers the greatest opportunity for improving overall profitability? So if you look at the different verticals or different API formulation and the exports, definitely margins in exports and formulation are better than the API.

30:28 Got it, sir. Thank you, Bajaj from my side. The next question is from the line of Sajal Kapoor from Antifragile Thinking. Please go ahead. Just one question for you, Rohan. I mean looking at the Y o Y gross margin because of West Asia crisis, it's I mean, it's down roughly, I think, two fifty basis points or maybe two twenty five basis points, give or take, Y o Y. And despite that, the EBITDA margins are still very sticky around 18%. I mean, is it purely a volume led? So higher sales spread across the fixed cost? Is that the reason why EBITDA did not fall two percent point in line with the gross margins? Or was there some operating leverage in addition to that? I mean, how I mean, what's the role of operating leverage?

31:25 I think that's precisely the question because lower gross margins should have reflected in the lower EBITDA margin as well. Yes. So I can attribute the EBITDA rearing more or less in a similar line as last quarter to the product mix. As you're aware, we did do a launch of cinnaboment in this quarter. So when there's a dip in the domestic API business, our export information business are able to cope up and cover up, and our margins are also good in those businesses. So there is an increase in export business in this quarter. So from that perspective, the EBITDA margin is holding true. From a gross margin perspective, I think there is a dip, but we expect it to be better or similar lines in the coming few quarters.

32:14 So, Ron, assuming that the West Asia crisis stays as is, right, there is absolutely no change in the second half, how confident are we in terms of maintaining, if not improving, this EBITDA margin for the remaining fiscal? We are pretty confident of maintaining this gross margin and EBITDA margins. We do have a vast product mix where we can calibrate it much better in the coming quarters so that we are able to maintain it. Okay. Okay. That's helpful. Okay. Thank you, sir. Thank you. Thank you. The next question is from the line of Rohit from iThought PMS. Please go ahead. Yeah. Good evening. I hope I'm audible.

32:59 Yes. You. So so, sir, just wanted to understand this... In API as a whole, like, right now, how many products do we have? And then specifically on the exports, what contribution would Magnesium will have to our to our API exports? Roughly, just... I don't want exact numbers, but just wanted to broad broad share. And what is driving this growth in the export segment? You can maybe share that as well. So we produce more than 50 APIs across the year, depending upon the requirement from the customers.

33:49 In that, if you see the magnesium alternate, which we supply to the patient holder in U. S, which contributes to around 11% to 12% of the overall turnover. Okay. And so what is driving the growth in API exports? As you as you as you... As I mentioned that we have already filed 110 DMF in different countries. So as and when we are getting approval, so that product we are able to export and we are getting new businesses from that. So whatever investments we have done in last one point five years or two years, the filing of DMF, that is now is supporting and it will support in future also.

34:45 Got it. And let's say this year or maybe next next year, in terms of this mix between domestic export and formulations, last year was 90, 10 or 89, 11 more towards API. And, of course, this quarter itself, we are at 24% in terms of combination. So where do you see this, let's say, FY '27 or FY '28 in terms of mix between API and combination? Of course, I'm aware that we are also ramping up our own API. So just wanted your sense, let's say, in that's why what is one... Let's say, FY '27 and '28, what kind of mix it would be? And let's say, once these plans start to come in and you have good approval, etcetera, let's say, three, four years out, let's say, the thousand grow number that you are targeting, what is the mix that you are looking at between APIs and combinations?

35:43 So as you know, we we manufacture API, and we manufacture formulation. Whatever formulation we sell with our backward indicate. We are not dependent on any other API, which is resource from outside. So that is a key strength. So we control the API, we control the formulation. So once the formulation business grows, similarly, the API business will also grow. So even today, we are in the range of 20% to 24% of formulation and rest is of API. So over the next three to four years, if you see, formation business will be anywhere between 45 to 50% and same thing with 50% to 55% of the API and 45% to 50% is of formulation.

36:33 Understood. And just to be clear, this formulation will be again mostly B2B where we'll provide to... It's called a CDMO business. It's a CDMO where we do our development, we give it to the like we gave cinobaram to the six of our partners. It will be from the CDMO, it will be from the formulation exports and from the oncology. So it's all formulation and also the instrument Right now, we don't have any exports, right, in terms of formulations today? No. We have started filing it. In next two years, we should have business from that. Got it. And sir, this from, I think, in the initial question to a participant earlier, some you mentioned the CapEx this year would be about INR70 crores to INR80 crores?

37:30 Yes. It's INR65 crores to INR80 crores is what I mentioned. INR65 crores to INR80 crores. And for your all these growth plans that you have to reach 1,000 crores, what kind of incremental CapEx after FY 'twenty seven do you anticipate? So as we mentioned in our previous last quarter that every year we'll be infusing around INR50 crores to INR60 crores to get that growth of INR1000 crores. So every year, you'll do around INR 60 crores to 60 crores of CapEx with this year being INR 65 crores to 80 crores. Is that how funds will be this? Yes. Got it.

38:18 That's it from my side. Thank you. Thank you. Thank you. The next question is from the line of Ayush from Wealth Management Family Office. Please go ahead. Hello. Am I audible? Yes. You are. Sir, congrats on a good set of numbers. So my question is on oncology plant, which are being commissioned in FY twenty eight. So for... So this plant is not for our own brand, but also for the CMO sector, CDMO sector. So is this understanding right? Yes. It is for the CDMO and for our own brand. Okay. Thank you. Thank you. Next, we have a follow-up question from the line of Bajaj from Ambit Asset Management. Please go ahead.

39:13 Yeah. Thank you, sir, for the opportunity once again. Sir, I just wanted to know what is the revenue that we would have booked from in September. And given that you got repeat orders, is it fair to say that the monthly run rate of this product may sort of keep on increasing so far in this financial year? As you must be aware that once the company launched first time, so the requirement is higher than the regular requirements. So these are new molecule in India, totally new. This molecule was not there. So Bajaj was the company who brought this molecule to India.

40:01 So depending upon the sales from our partner, we can expect more orders. But this is a class drug where once the patient takes the tablet, he has to continue with that because it's an antisense drug. Sure. Sure. But sir, any quantification on the revenue we can give? How much can it do maybe in FY 'twenty seven or in FY 'twenty eight or difficult to quantify? It will be very difficult for the next two years, but it is going, I can say. Okay. Secondly, sir, you mentioned that you hired a lot of people on the R and D side as well as on the CXO side. You have been strengthening the organization.

40:48 So just wanted to understand how do we retain them given that we are such a small company, and we have been... Have hired so many senior people. So what are we doing for them to stay back with us? Obviously, we would have promised them the growth path in terms of our profitability and revenue. But, ultimately, given that these are senior people, they also want long term incentives. So if you can spend some time on that, that would be helpful, and that would be my last question. So to retain the good people, the company has made some structures. Different person has a different requirement, right? So with some, we have done with incentivizing them.

41:36 Somebody we have So this way, we try to retain them for a longer period. Understood. Right, I didn't get that. All these incentives are on performing basis. Performance basis. Okay. Great, sir. Thank you very much and all the best. Thank you. The next question is from the line of Bajaj Sharma from BD Capital. Congratulations on the good start up numbers. I have two questions with me. So the first question is that the company has made progress on regulatory approvals across Brazil, South Korea, and Egypt. So, like, are these developments now beginning to translate into commercial inquiries or orders?

42:36 And also, which of these markets do you see contributing meaningfully in the near term? Almost we have filed in different countries. We have filed in Korea. We have filed in Europe. Now we'll be filing in Brazil, Mexico. So already, we have filed 17 product in Korea and 10 DMF in Europe. So hopefully, to get the business from where we have filed the first, we'll get a business over there. But overall, the product which we have chose has a very good market overall. So there will be like demand, which country has more demand, we'll get more business from that. And Korea already has started some businesses.

43:23 So hopefully, we'll see a good result in next coming years. Understood, sir. And my next question is that looking at the overall performance in h one f y twenty seven. So, like, what gives management confidence about sustaining this growth in the second half? And also, are there any specific products, business segments or external factors that investors should particularly track going forward? So as we mentioned that we have built a strong R and D team, and we are going to a new segment, peptides and new molecules. So that will be giving us a sustainability in coming years.

44:21 The next question is from the line of Javed Ansari from Capital. My first question is as related to peptide semaglutide, as many of the many other Indian players are entering into this market. So how is management tackling this decision? How they are seeing this? So as you mentioned, there are many companies has entered, but they are all into combination of injectables. The first thing is that the patient which is off is for the injectable. And many companies have launched injectables. We are into more into API.

45:06 The plant which we have built is for the API. If you see, there are very, very less people into API. So whoever is launching the product, you need API. Okay. Understood. And my next question is with the oncology API facility expected to commercialize. So can I know what what what will be the revenue mix from specialized API or or generic API versus generic API? It's very difficult, sir. It's a mix again. It's a totally a mix. Okay. Sir. Thank you. Thank you. Ladies and gentlemen, we will take it as the last question for today. I would now like to hand the conference over to the management for the closing comments.

45:53 Over to you, sir. Thank you, all our investors. Thank you for participating in this call and being part of this call. Wishing a very happy Dasir and Advaan. Thank you. Thank you. On behalf of MUFG Investor Relations, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.

Follow Bajaj Healthcare Ltd into a list and get an email when it puts out news.

Latest news releases

Companies on this call

More from Bajaj Healthcare Ltd